All verified mentions of this organization in source documents.
LambdaVision has pre-booked commercial space in low-Earth orbit through partnerships with Starlab Space LLC, a joint venture led by Voyager Technologies.
To date, LambdaVision has secured $22.0 million in funding.
LambdaVision has launched nine missions to the International Space Station.
Reduced gravity in low-Earth orbit improves homogeneity, stability, and performance of thin films such as LambdaVision’s protein-based artificial retina.
LambdaVision’s layer-by-layer protein manufacturing platform has potential applications for highly uniform, stable protein films in biosensors, optical systems, tissue engineering, and drug delivery.
LambdaVision plans to scale manufacturing of its protein-based artificial retina in space to benefit people with retinal degenerative diseases on Earth.
LambdaVision’s protein-based artificial retina uses proteins similar to the visual pigment rhodopsin to mimic the light-absorbing properties of human photoreceptors and replace the function of damaged retinal cells.
LambdaVision recently closed a $7 million seed funding round co-led by Seven Seven Six and Aurelia Foundry Fund with additional support from Seraphim Space, providing runway into 2027.
Nicole Wagner, Ph.D., is CEO of LambdaVision.
LambdaVision’s space-based manufacturing plans are intended to prepare the company for the scheduled 2030 retirement of the International Space Station.
LambdaVision has reserved payload slots and commercial space on Starlab’s next-generation commercial space station.
LambdaVision developed and refined its process of manufacturing artificial retinas on the ISS.
Manufacturing in microgravity allows LambdaVision to build a higher-performance membrane with increased stability compared to manufacturing on Earth.
LambdaVision closed a $7 million seed round in November.
LambdaVision has flown nine missions to the International Space Station.
LambdaVision plans to scale up manufacturing in low Earth orbit (LEO) for artificial retinas.
LambdaVision has flown nine missions to the International Space Station (ISS) to produce a 200-layer protein thin film as a precursor to an artificial retina.
The funding will allow LambdaVision to continue operations through 2027.
LambdaVision is partnered with microgravity research firm Space Tango for its in-space manufacturing process.
LambdaVision plans to produce artificial retinas, which are easier to manufacture in the microgravity environment of space.